A terceira newsletter do RIDAI, vem uma vez comunicar a nossa experiência inter pares, e aos nossos parceiros: doentes, indústria, entidades reguladoras e comunidade em geral. O RIDAI enquanto plataforma tem um crescimento continuado, como se poderá verificar nas páginas seguintes. Uma vez que o esforço de todos continua a incidir sobre a terapêutica biotecnológica, [...]
Caros colegas, Esta é a segunda newsletter do RIDAI e a segunda publicada no ano de 2016, cumprindo o objectivo de comunicar com regularidade a nossa experiência e os nossos resultados, cientes da importância desse conhecimento inter pares, bem como para os nossos parceiros: doentes, indústria, entidades reguladoras e comunidade em geral. O RIDAI continua [...]
WAidid suggests the reading of the first European guidelines on adult and elderly vaccinations just published 'Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)'. Diphtheria, tetanus, pertussis, influenza, pneumococcal disease, herpes zoster are among [...]
NEW YORK (Reuters Health) - Sifalimumab, an anti-interferon alpha monoclonal antibody, may lead to some improvement in patients with systemic lupus erythematosus (SLE), according to a new trial. In a paper online March 23 in Annals of the Rheumatic Diseases, Dr. Munther Khamashta of King's College London and colleagues note that treatment of SLE presents a [...]
Consequences for Response Prediction to Rituximab Tamarah D de Jong; Saskia Vosslamber; Marjolein Blits; Gertjan Wolbink; Mike T Nurmohamed; Conny J van der Laken; Gerrit Jansen; Alexandre E Voskuyl; Cornelis L Verweij Abstract Introduction Elevated type I interferon (IFN) response gene (IRG) expression has proven clinical relevance in predicting rituximab non-response in rheumatoid arthritis (RA). Interference between [...]
Robert BM Landewé Abstract On behalf of the American College of Rheumatology (ACR), Saaget al. recently published recommendations for the use of nonbiologic and biologic DMARDs in rheumatoid arthritis (RA).1 A group of experts was charged with the enormous task of bringing evidence-based clarity to the multitude of treatment options for RA and providing guidance to practicing [...]
Medicare and Medicaid have been the talk of the nation since Republican presidential hopeful Mitt Romney named Rep. Paul Ryan (R-Wisc.) as his running mate. Rep. Ryan became a key leader of the Republican party when he proposed his Path to Prosperity, a GOP-supported budget plan. His plan also provided alternative reforms to those in the Affordable Care Act. For example, the plan includes turning [...]
Joel M Kremer Abstract Weinblatt and colleagues have studied the efficacy and safety of etanercept 50 mg twice weekly in comparison with etanercept 50 mg once weekly in patients with longstanding rheumatoid arthritis. The study failed to demonstrate any clinically meaningful or statistically significant benefit of the use of the twice weekly dosage. There was also [...]
Abstract Introduction: In vitro apoptosis of peripheral monocytes in rheumatoid arthritis (RA) is disturbed and influenced by cytokine production and transmembrane TNF (tmTNF) reverse signaling. The goal of the study was the analysis of the predictive value of the rate of in vitro apoptosis for the therapeutic response to anti-TNF treatment. Methods: Spontaneous and tmTNF reverse signaling-induced apoptosis [...]
Abstract Adipo(cyto)kines are mostly produced by adipose tissue and orchestrate the adverse impact of excess adiposity on cardiovascular risk. Adipokines also contribute importantly to the pathophysiology of rheumatoid arthritis. Congruent with data reported in previous investigations, Kang and colleagues report in this issue of Arthritis Research & Therapy that adipokine concentrations are further associated with metabolic risk and [...]